Media

January 17, 2023 | In the News
Cancer Biotech Elicio Finds Path to Public Markets Via Angion Reverse Merger

MED CITY NEWS: Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes.

November 9, 2022 | In the News
Leveraging Lymph Nodes With Elicio’s Dr. Peter DeMuth

BUSINESS OF BIOTECH PODCAST: Chief Scientific Officer Peter DeMuth, PhD at Elicio HQ in Boston talks about how the platform works, and how it’s driving rapid clinical progress for the company’s robust pipeline of therapeutic vaccines in oncology.

November 3, 2022 | Publication
A Lymph Node Targeted Adjuvant and Engineered Subunit Vaccine Promotes Potent Immunity to Epstein-Barr Virus in HLA-expressing Mice

Research Square, Dasari, et. al.

October 28, 2022 | Publication
Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates

NPJ Vaccines – 2022
Seenappa LM, Jakubowski A, Steinbuck MP, et al.

September 23, 2022 | In the News
Cancer Vaccines Push Toward Viability with New Approaches and Targets

BIOSPACE: The advances in immuno-oncology and adaptive cell therapy that began about a decade ago, however, are enabling fresh, biology-driven approaches with the potential to bring therapeutic cancer vaccines much closer to fruition.

September 20, 2022 | In the News
Elicio Receives $2.8M Grant for Cancer Vaccine Development

PRECISION ONCOLOGY NEWS: Elicio Therapeutics said Tuesday that it received a $2.8 million grant from the Gastro-Intestinal Research Foundation (GIRF) in Chicago to fund research for two therapeutic cancer vaccines.

July 20, 2022 | Publication
Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity

Scientific Translational Medicine, Hartwell, et. al.

July 6, 2022 | Publication
A lymph node targeted CpG, TLR9 agonist induces potent activation of lymphaticinnate immune responses resulting in robust cellular and humoral immunity to SARS-CoV-2

Scientific Poster

July 6, 2022 | Publication
A Lymph Node Targeted Engineered Subunit Antigen and Molecular Adjuvant Vaccine Promotes Potent Cellular and Humoral Immunity to Epstein Barr Virus in HLA expressing Mice

Scientific Poster

July 6, 2022 | Publication
A Lymph Node Targeted Protein Subunit Vaccine Induces Robust Cellular and Humoral Immunity to SARS-CoV-2 in Non-human Primates

Scientific Poster

Secret Link